IMMUTEP LIMITED — Investor Presentation 2021

Nov 16, 2021

==> picture [38 x 37] intentionally omitted <==

SITC 2021 Results: Management Update

GLOBAL WEBCAST

Date & Time: 8.00 am AEDT (Sydney) Wednesday 17 November 2021 4.00 pm EST (New York) Tuesday 16 November 2021 10.00 pm CET (Berlin) Tuesday 16 November 2021 Register: https://fnn.webex.com/fnn/onstage/g.php?MTID=ef12af93633b5d17a2e4e176fcac2f070

A replay of the webcast will also be available at www.immutep.com

(ASX: IMM, NASDAQ: IMMP)

Notice: Forward Looking Statements

==> picture [170 x 60] intentionally omitted <==

The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Immutep and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company’s filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Immutep’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Immutep’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Immutep. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This presentation is authorised for release by the CEO of Immutep Limited.

2

Overview

==> picture [170 x 60] intentionally omitted <==

Immutep

is an innovative biotechnology company developing novel immunotherapies for cancer and autoimmune disease

==> picture [111 x 97] intentionally omitted <==

Globally active

==> picture [186 x 201] intentionally omitted <==

==> picture [99 x 69] intentionally omitted <==

Leadership position in LAG-3

with 4 product candidates in immuno-oncology and autoimmune disease

Clinical Potential

Immutep’s product candidates have demonstrated clinical potential in a range of indications with high unmet need

Collaborating with industry leaders

==> picture [94 x 21] intentionally omitted <==

==> picture [48 x 30] intentionally omitted <==

==> picture [94 x 34] intentionally omitted <==

==> picture [83 x 34] intentionally omitted <==

==> picture [119 x 46] intentionally omitted <==

==> picture [59 x 18] intentionally omitted <==

==> picture [76 x 24] intentionally omitted <==

==> picture [80 x 17] intentionally omitted <==

==> picture [134 x 138] intentionally omitted <==

LAG-3 Pioneer

French immunologist

Prof. Frédéric Triebel, Immutep CMO & CSO

3

==> picture [169 x 59] intentionally omitted <==

LAG-3 Overview & Product Candidates

4

LAG-3 Therapeutic Landscape Overview

==> picture [170 x 60] intentionally omitted <==

Agonist
	Company	Program	Preclinical	Phase I	Phase II	Phase III	Total Trials	Patients
		Eftilagimod Alpha(5)		10	4		14	967
	BMS	Relatlimab(6)		7	32	2	41	9,775
		Favezelimab		1	5	~~PDUFA oal date~~	6	1066
Antagonist Agonist Depleting AB Autoimmune Oncology	Merck & Co. Inc.
		Ieramilimab		1	4	~~g~~ March 19, 2022	5	952
	Macrogenics	Tebotelimab		3	3		6	1422
	H-L Roche	RO7247669		1	2		3	538
	B.I.	BI754111		4	1		5	649
	Regeneron(1)	Fianlimab		1	1		2	836
	Innovent	IBI110		1	1		2	328
	Tesaro(3)	TSR-033		1	1		2	139
	Incyte	INCAGN02385		1	1		2	74
	Symphogen(2)	SYM022		3			3	169
	F-star	FS-118		2			2	102
	Xencor	XmAb-22841		1			1	242
		IMP761					--	--
	(4)	GSK2831781 (IMP731)		2	1		3	207

Sources: GlobalData, Company websites, clinicaltrials.gov, and sec.gov, as of 25th October 2021. The green bars above represent programs conducted by Immutep &/or its partners. Total trials includes all active, completed &/or inactive trials. Patient totals are based on estimated total enrolled &/or to be enrolled. Not a complete list of currently existing LAG-3 products.

• 1) As of January 7, 2019 Regeneron is in full control of program and continuing development

• (https://www.sec.gov/Archives/edgar/data/872589/000110465919000977/a19-1325_18k.htm)

• 2) On 3 Apr. 2020 Les Laboratoires Servier acquired Symphogen

• 3) Tesaro was acquired by and is now part of GSK (www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-oftesaro-an-oncology-focused-biopharmaceutical-company/ )

• 4) Includes two completed Phase I studies and one discontinued Phase 2 study 5) Including IITs, one planned trials (MBC trial by EOC)

• 6) RELATIVITY-047 (https://investors.bms.com/iframes/press-releases/press-release-details/2021/Bristol-Myers-Squibb-Announces-RELATIVITY047-a-Trial-Evaluating-Anti-LAG-3-Antibody-Relatlimab-and-Opdivo-nivolumab-in-Patients-with-Previously-Untreated-Metastatic-or-UnresectableMelanoma-Meets-Primary-Endpoint-of-Progression-Free-Survival/default.aspx)

5

==> picture [169 x 59] intentionally omitted <==

Eftilagimod Alpha Bringing APC Activation into Oncology

Eftilagimod alpha ~ Efti ~ IMP321

6

Efti: an Innovative LAG-3 I-O Product Candidate

==> picture [170 x 60] intentionally omitted <==

• Efti is a soluble LAG-3 protein targeting a subset of MHC class II on APC

• Potentially synergistic with other therapeutic agents, e.g. Immuno-Oncology (I-O) agents or chemotherapies

“PUSHING THE ACCELERATOR ON IMMUNE RESPONSES”

“RELEASING THE BRAKE ON THE T CELL”

==> picture [317 x 212] intentionally omitted <==

Efti is an MHC II agonist: APC activator

• boost and sustain the CD8[+] T cell responses

• activate multiple immune cell subsets

LAG-3 antagonist , or blocking, antibodies: Immune checkpoint inhibitor

• increase cytotoxicity of the pre-existing CD8 T cell response

Notes:

7

• APC: antigen presenting cell

Clinical Development

Efti: Main Trials*

==> picture [170 x 60] intentionally omitted <==

Oncology	Program	Preclinical	Phase I	Phase II	Late Stage(5)	Commercial Rights
	Eftilagimod Alpha (Efti or IMP321) APC activating soluble LAG-3 Protein	Metastatic Breast Cancer ( AIPAC-003	Chemo – IO)(1)			Global Rights
		Metastatic Breast Cancer ( AIPAC	Chemo – IO)
		Head and Neck Squamous TACTI-003	Cell Carcinoma (IO – IO)(2)
		Head and Neck Squamous TACTI-002	Cell Carcinoma (IO – IO)(2)
		Non-Small-Cell Lung Carci TACTI-002	noma (IO – IO)(2)
		Solid Tumors (IO – IO – C INSIGHT-003	hemo)(3)		§
		Solid Tumors (IO – IO)(3), (4 INSIGHT-004	a)
		Solid Tumors (IO – IO)(1), (3 INSIGHT-005	), (4b)
		Melanoma (IO – IO) (2) TACTI-mel
		Solid Tumors (Cancer Vacc YNP01 / YCP02 / CRESCE	ine)(5a) NT 1
		Metastatic Breast Cancer (	Chemo – IO)(5b)		~~§~~	Chinese Rights
Notes:

Notes:

• (4) a) In combination with BAVENCIO® (avelumab); b) in combination with Bintrafusp alfa (5) (6) Late stage refers to Phase IIb clinical trials or more clinically advanced clinical trials

• Information in pipeline chart current as at November 2021. AIPAC-003 and INSIGHT-005 trial initiation are subject to further approvals. (1) Planned trial (2) In combination with KEYTRUDA® (pembrolizumab)

• a) Conducted by CYTLIMIC in Japan; b) Conducted by EOC in China. Immutep has no control over either of these trials. Late stage refers to Phase IIb clinical trials or more clinically advanced clinical trials

8

Clinical Development

Operational Update

==> picture [170 x 60] intentionally omitted <==

TACTI-002 ✓ Recruitment into Part A (1st line NSCLC) is expected to be completed ahead of time, due to great interest from sites. ✓ 70+ of 74 patients for part A extension already enrolled. TACTI-003 ✓ Full CTA approvals received in 5 of 8 countries → no roadblocks or any major comments received from authorities. ✓ Recruitment initiated, first patients randomized. INSIGHT ✓ INSIGHT-003 (efti+SoC (e.g. doublet chemo + PD-1) in e.g. 1st line NSCLC) has enrolled already 5 patients . ✓ Preparation for INSIGHT-005 collaboration with Merck KGaA are ongoing, but under review due to bintrafusp alfa performance. AIPAC-003 ✓ Positive feedback from EMA received. ✓ FDA discussion ongoing as planned.

9

==> picture [169 x 59] intentionally omitted <==

Efti + Chemo Combination AIPAC trial

Final OS results presented at SITC, 10-14 November 2021

10

Goal: Improving OS while maintaining QoL in HR[+] /HER2[–] MBC patients

==> picture [170 x 60] intentionally omitted <==

Epidemiology:

• Breast cancer (BC) is the most frequently diagnosed cancer . More than 2 million breast cancer (thereof ~70% HR[+] /HER2[--] ) diagnoses per annum worldwide.

• Up to 550,000 patients in total and app. 350,000 patients younger than 65 develop metastatic disease and are eligible to receive chemotherapy[(1) (2)]

==> picture [487 x 284] intentionally omitted <==

----- Start of picture text -----

~10%
~35%
Lack of Innovation
Weekly paclitaxel well
~55%
established SOC
----- End of picture text -----

Notes

(1) Source: WHO Global Cancer Observatory 2020 and Informa Intelligence October 2020 (2) Wang et al. BMC Cancer (2019) 19:1091

11

Efti: AIPAC (Phase IIb) design

==> picture [170 x 60] intentionally omitted <==

AIPAC: Active Immunotherapy PAClitaxel in HER2[–] / HR[+] metastatic breast cancer (MBC)

==> picture [468 x 202] intentionally omitted <==

Hypothesis-Generating Study

Primary endpoint[(] *[)] (presented Mar. 2020) included:

• Assessment of Progression-Free Survival (PFS)

Secondary endpoints[(] *[)] (presented Dec. 2020) included:

• Overall Survival (OS)

• Safety and tolerability

• Overall Response Rate (ORR) and other efficacy parameters

• Biomarker and Immune Monitoring

==> picture [204 x 176] intentionally omitted <==

Fact sheet

• ✓ Conducted in 7 EU countries

• ✓ Local and blinded independent central read

• ✓ Last Patient In enrolled Jun. 2019

• ✓ Primary analysis PFS (immature OS) Mar. 2020

• ✓ Follow-up 1 analysis OS Sep. 2020 (SABCS Dec. 2020) – ~60% OS events

• ✓ Final OS analysis at SITC 2021

Notes:

• No hypothesis testing ORR – overall response rate, DCR – disease control rate, PFS – progression free survival, OS – overall survival, QoL – Quality of life

12

AIPAC Phase IIb Clinical Results

Baseline Characteristics

==> picture [170 x 60] intentionally omitted <==

• ➢ Well balanced treatment groups.

➢ Difficult to treat patient population:

• Very late stage disease: 92% with visceral disease and 69% with elevated LDH

• Heavily pre-treated subjects: 84% endocrine resistant; 44% received prior CDK 4/6; median of 2 prior systemic anticancer regimens.

• HR[+] /HER2[–] tumor is traditionally not considered immunogenic.

• ➢ 227 patients were randomized to efti (N=114) or to placebo (N=113) between January 2017July 2019. All except one patient received at least 1 dose of study medication and were included in the full analysis and safety populations.

==> picture [489 x 379] intentionally omitted <==

Notes:

¶ Central assessment performed on available and evaluable primary or metastatic tissues (n=169). Classified using PgR and Ki67 index according to St Gallen International Expert Consensus guidelines[1] .

Δ Defined according to ESMO Internal Consensus Guidelines (Advanced Breast Cancer 4)2.

13

AIPAC Phase IIb Clinical Results

Outstanding Safety Profile

==> picture [170 x 60] intentionally omitted <==

Most common (≥15%) TEAEs in any arm

Summary of treatment-emergent adverse events (TEAEs) ¶	Efti + Paclitaxel N=114, n (%)	Placebo + Paclitaxel N=112, n (%)
≥1 TEAE	113 (99.1)	112 (100)
≥1 TEAE leading to death	2 (1.8)	3 (2.7)
≥1 TEAE leading to efti/placebo discontinuation	6 (5.3)	7 (6.3)
≥1 Grade ≥3 TEAE	78 (68.4)	73 (65.2)

• No fatal TEAE related to efti

• • 3 pts discontinued due to hypersenstivity reactions developing after efti injections and 4 pts due to paclitaxel-induced hypersensitivity, respectively

• •

Most common efti related adverse event was any kind of local injection site reaction up to grade 3 reported in 75 (65.8%) pts in the efti arm

Notes:

14

ORR – overall response rate, DCR – disease control rate, PFS – progression free survival, OS – overall survival, QoL – Quality of life

Overall Unselected Population*

Improving OS with better QoL

==> picture [396 x 326] intentionally omitted <==

• Increase in OS: +2.9 months from median of 17.5 (95% CI: 12.921.9) in placebo to 20.4 (95% CI: 14.3 -25.1) in the efti group.

• Post-study treatment similar: 86 % (efti) vs. 90 %(placebo); majority received chemotherapy 70.2% (efti) vs. 76.8% (placebo)

==> picture [170 x 60] intentionally omitted <==

Global Health Status / QoL QLQC30-B23

==> picture [275 x 304] intentionally omitted <==

----- Start of picture text -----


----- End of picture text -----*

• Preserving QoL in the efti arm, while significant deterioration of QoL (QLQ-C30-B23) observed in the placebo group at 6 months.

• Note: Paclitaxel treatment intensity was similar between groups

Notes:

• These results were presented at SITC 2021. Database cut-off date was May 14, 2021 (73% of events) with minimum follow up of 22 months

15

AIPAC Phase IIb Clinical Results

Immune Monitoring on Fresh Blood (up to 70 patients)

==> picture [170 x 60] intentionally omitted <==

Significant Increase of CD8+ T Cell Count

Significant Correlation:

Minimal Residual Effect: samples taken just before next treatment

==> picture [264 x 78] intentionally omitted <==

==> picture [218 x 257] intentionally omitted <==

Proof of Principle Number of T cells increased in efti group, especially cytotoxic CD8+ T cells

OS and cytotoxic CD8[+] T cell count

==> picture [321 x 332] intentionally omitted <==

----- Start of picture text -----

Placebo Rho= -0.2; p= 0.5
30 mg efti Rho= 0.6; p= 0.007
1000
500
300
100
10 20 30 40 50
Overall survival (months)
Proof of Concept
Increased number of cytotoxic CD8+ T cells
correlated with improved OS in the efti arm
/L of blood)
6
(10
CD8 T cell count at 6 months
----- End of picture text -----

Notes:

• These results were presented at SITC 2021. Database cut-off date was May 14, 2021

16

Prespecified Subgroups*

Exploratory Analysis

==> picture [170 x 60] intentionally omitted <==

Exploratory multivariate analyses → Prior CDK 4/6 treatment is an independent poor prognostic factor with a 37% increase in risk for death .

• Prior CDK 4/6 has a negative impact on OS in placebo group (median reduced from 20.4 to 14.9 months), but not in the efti group (median OS 21.9 vs. 20.2 months).

• CDK4/6 treatment are now standard, and most patients will have received it → favorable for efti.

==> picture [481 x 214] intentionally omitted <==

• Prespecified (prior to unblinding) exploratory univariate analysis showed that younger patients (<65 years), those with low baseline monocytes (<0.25/nL) or breast cancer subtype luminal B had significant and clinical meaningful improvement in median OS compared to placebo.

• In a post-hoc multivariate analysis “no prior taxanes” were found to be an additional predictive marker

Notes:

• These results were presented at SITC 2021. Database cut-off date was May 14, 2021 (73% of events) with minimum follow up of 22 months

17

Prespecified Subgroup <65 years*

Clinically meaningful improvement for OS, PFS and ORR

==> picture [170 x 60] intentionally omitted <==

==> picture [420 x 49] intentionally omitted <==

----- Start of picture text -----

+7.5 months median OS (HR 0.66; p=0.017)
----- End of picture text -----

==> picture [361 x 297] intentionally omitted <==

• Prespecified subgroup showed significant (p=0.017, one-sided) improvement in OS with a HR of 0.66 (95% CI: 0.45-0.97).

• ESMO scale of magnitude** = level 4/5 (would be very supportive for reimbursement).

	mOS	mPFS	ORR
Benefit	+7.5 months HR 0.66 (p=0.02)	+2.0 months HR 0.77 (p=0.07)	+8% (46% vs. 38%)
Effect of age on OS

==> picture [311 x 198] intentionally omitted <==

• HR point estimates for different age groups.

• Age had an almost linear effect on HR for OS.

Notes:

• ** Company assessment. ESMO-MCBS used for reimbursement in Europe: https://www.esmo.org/guidelines/esmo-mcbs/scale-evaluation-forms-v1.0-v1.1

• These results were presented at SITC 2021. Database cut-off date was May 14, 2021

18

Prespecified Subgroup Low Monocytes*

Clinically meaningful improvement for all efficacy parameters

==> picture [170 x 60] intentionally omitted <==

+19.6 months median OS (HR 0.44; p=0.008)

	Efti + Paclitaxel	Placebo + Paclitaxel	Benefit
mOS	32.5 months	12.9 months	+19.6 months HR 0.44 (p=0.008)
mPFS	7.5 months	5.2 months	+2.3 months HR 0.40 (p=0.006)
ORR	44%	32%	+12%

• Clinically meaningful, absolute and relative improvement for all efficacy parameters.

• Statistical significance for PFS and OS.

• ESMO scale of magnitude** = level 4/5 (would be very supportive for reimbursement).

Notes:

** Company assessment. ESMO-MCBS used for reimbursement in Europe: https://www.esmo.org/guidelines/esmo-mcbs/scale-evaluation-forms-v1.0-v1.1

• Database cut-off date was May 14, 2021

19

Prespecified Subgroup Luminal B*

Overall Survival

==> picture [170 x 60] intentionally omitted <==

+4.2 months median OS (HR 0.67, p=0.049)

==> picture [405 x 246] intentionally omitted <==

----- Start of picture text -----

Efti + Paclitaxel Placebo + Paclitaxel Benefit
+4.2 months
mOS 16.8 months 12.6 months
HR 0.67 (p=0.049)
+1.6 months
mPFS 7.2 months 5.6 months
HR 0.69 (p=0.158)
ORR 43% 33% +10%
•
Clinically meaningful improvement.
•
Statistical significance for OS.
----- End of picture text -----

• ESMO scale of magnitude** = = level 3/5 (would be supportive for reimbursement).

Notes:

** Company assessment. ESMO-MCBS used for reimbursement in Europe: https://www.esmo.org/guidelines/esmo-mcbs/scale-evaluation-forms-v1.0-v1.1

• Database cut-off date was May 14, 2021

20

Prespecified Subgroup No Prior Taxane*

Overall Survival

==> picture [170 x 60] intentionally omitted <==

+4.8 months median OS (HR 0.74, p=0.076)

==> picture [405 x 131] intentionally omitted <==

----- Start of picture text -----

Efti + Paclitaxel Placebo + Paclitaxel Benefit
+4.8 months
mOS 22.3 months 17.5 months
HR 0.74 (p=0.08)
+0.2 months
mPFS 7.4 months 7.2 months
HR 0.87 (p=0.229)
----- End of picture text -----

• Clinically meaningful improvement.

• Important in multivariate predictive model

• ESMO scale of magnitude** = = level 3/5 (would be supportive for reimbursement).

Notes:

• Database cut-off date was May 14, 2021

21

AIPAC-003: Phase III in MBC

General Concept (subject to further regulatory interactions)

==> picture [170 x 60] intentionally omitted <==

==> picture [575 x 398] intentionally omitted <==

----- Start of picture text -----

1) Primary Endpoint: Overall Survival
•
Preferred endpoint for Phase III and approval by regulatory agencies in
such a patient population.
•
Seems to be a better fit for active immunotherapies such as efti.
2) Treatment
•
Paclitaxel will be allowed to be continued beyond 6 cycles to
accommodate for EU & US standards and as a lesson from AIPAC.
3) Patient Population on Target
•
Immutep will define the patient population and statistical read-out in a way
to increase likelihood of success.
4) Statistical Design
•
Will be robust and pre-agreed with regulatory agencies to ensure success
later during MAA/BLA procedures.
----- End of picture text -----

22

==> picture [169 x 59] intentionally omitted <==

Efti + anti-PD-1 Combination TACTI-002 trial Update from SITC, 10-14 November 2021

23

TACTI-002 (Phase II)

Design & Status

==> picture [170 x 60] intentionally omitted <==

TACTI-002: Two ACTive Immunotherapeutics in NSCLC and HNSCC

==> picture [530 x 270] intentionally omitted <==

----- Start of picture text -----

UNSELECTED FOR PD-L1
PART A:
S
1 [ST] LINE MET. NSCLC
C
R
PART B: COMBINED
E
2 [ND] LINE MET. NSCLC, IMMUNOTHERAPY
E
PEMBROLIZUMAB + EFTI FOR 12
N REFRACTORY TO PD-1/PD-L1 MONTHS + 12 MONTHS
TARGETING THERAPY PEMBROLIZUMAB MONO
I
N
PART C:
G
2 [ND] LINE MET. HNSCC AFTER Recruitment Status Report
PLATINUM THERAPY
✓ Fully approved in all countries
----- End of picture text -----

In collaboration with

==> picture [188 x 49] intentionally omitted <==

ORR, PFS, OS, PK, biomarker, safety and tolerability

Sites in Europe / US / Australia

==> picture [224 x 156] intentionally omitted <==

• ✓ Up to 183 patients in three indications

30 mg efti (IMP321) s.c. Treatment 200 mg pembrolizumab (Keytruda[] ) i.v.

• Part A (N=36) completed; extension cohort (N=74 recruiting)

• ✓ Part C (N=39) completed

• ✓ Part B (N=36); completed

Notes:

24

ORR – overall response rate, DCR – disease control rate, PFS – progression free survival, OS – overall survival, QoL – Quality of life

TACTI-002 Results[(1)]

2[nd] line HNSCC (Part C)

==> picture [170 x 60] intentionally omitted <==

• ORR (iRECIST) in ITT of 29.7% and 35.5% evaluable pts

• Responses are deep with 5 (13.5%) CRs and long lasting

==> picture [300 x 188] intentionally omitted <==

• ORR of 64.3% (40.7) in pts with CPS ≥ 20 (≥1)

==> picture [328 x 184] intentionally omitted <==

• OS rates at 12 months for all PD-L1 groups in the range of 50% or above

• … patients still under therapy

Notes:

• (1) Database cut-off date was August 4, 2021 (efficacy)

25 Graphs represent all patients with at least one post baseline assessment. One patient has no official RECIST assessment as this was done < 6 weeks and this does not qualify according to RECIST. Per local investigator assessment.

TACTI-002 Results[(1)]

2[nd] line HNSCC (Part C), DoR and Benchmarking

==> picture [170 x 60] intentionally omitted <==

Duration of Response (DoR) for confirmed responders (N=10)

Benchmarking against Pembro

• ORR clearly higher (≥ factor 2) in all PD-L1 subgroups and overall

• PFS and OS rates at 6 and12 months respectively are higher in all PD-L1 subgroups and overall with efti combination

==> picture [192 x 275] intentionally omitted <==

• Median duration of response not yet reached

• all ongoing responses lasting 9+ months

	**PD-L1 (CPS) **	Pembro alone**	TACTI-002
ORR (%)	≥ 20	21.9%	64.3%*
	≥ 1	17.3%(2% CR)	40.7%(20.8% CR)
	Overallpop.	14.6%	35.5%#
mDoR (mths)	Overall pop.	18.4	Not reached with min. 9+ months at cut-off

Notes:

(1) Database cut-off date was August 4, 2021 (efficacy)

26 * - only patients evaluated where PD-L1 results available (N=14 for CPS ≥ 20) (N=27 for CPS ≥ 20); # - ITT(N=37); ** Data for pembro derived from KN040 (EEW Cohen et al., The Lancet 2018)

1[st] line HNSCC

Treatment options and positioning for efti + pembro

==> picture [170 x 60] intentionally omitted <==

==> picture [772 x 199] intentionally omitted <==

----- Start of picture text -----

Median OS from KN-048 [(1)] , Median DoR from KN-048 [(1)] ,
unselected for PD-L1 unselected for PD-L1
Chemo +
10.7-11.0 months 4.3
Cetuximab
11.6 months Pembrolizumab 22.6
to 14.9 for CPS ≥ 20
Chemo +
13.0 months 6.7
Pembrolizumab
to 14.7 for CPS ≥ 20
----- End of picture text -----

➢ OS slightly improved by ~2 months with chemo + pembro, but pembro alone noninferior to chemo

• ➢ Substantially more toxicities in the chemo + pembro setting compared to pembro alone

• → Buy moderate OS benefit with a lot add. toxicity

• ➢ ORR increased with chemo plus pembro (36% vs. 17% pembro alone)[(1)]

• ➢ DoR drops dramatically if you add chemo → not the case with efti

• → Buy ORR by much shorter DoR → less benefit for pts on the long run and may explain moderate OS improvement

Combination of efti + pembro May lead to higher ORR with same DoR and excellent safety profile

Notes:

(1) B Burtness et al.: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet 2019, https://doi.org/10.1016/S0140-

27

TACTI-003 Trial in 1[st] line HNSCC

Current Design + Status

==> picture [170 x 60] intentionally omitted <==

==> picture [525 x 452] intentionally omitted <==

In collaboration with

==> picture [213 x 56] intentionally omitted <==

Design:

• Randomised study with ORR as primary endpoint

• • Sites worldwide (AU, US, Europe)

• • Approx. 154 pts: either to be randomized to have sufficient pts in each group or in an experimental arm

• Status: ▪ Ongoing, recruiting.

• ▪ Fast Track designation granted by FDA in April 2021

28

==> picture [169 x 59] intentionally omitted <==

Summary and Outlook

29

Near-Term Milestones

Advancing Registration Relevant Trials

2021 till today

• ✓ Final Results from randomized, placebo controlled MBC trial (AIPAC)

• ✓ Fast Track designation in 1st line HNSCC from US FDA

• ✓ TACTI-002 – recruitment & data delivered e.g. at ASCO & SITC for

• ✓2[nd] line NSCLC

• ✓2[nd] line HNSCC

• ✓ TACTI-003 – Start randomized trial in 1[st] line HNSCC

• ✓ Final results of INSIGHT-004

• ✓ Progress from IMP761

• ✓ Expansion of IP portfolio

• ✓ Strong financial position

==> picture [170 x 60] intentionally omitted <==

Remainder of 2021 and 2022

Registration relevant trials

Phase III preparations in MBC (AIPAC-003)

• 1[st] line HNSCC: Recruitment and updates from randomized trial (TACTI-003)

• 1[st] line NSCLC: Completion of recruitment & first data from the extension cohort (TACTI-002)

Ongoing regulatory (EMA/FDA) engagement

INSIGHT-003: Data from Efti + a-PD-1 + Chemo combination

Extension of IP portfolio

Potential new studies (financed)

Updates from IMP761

Updates from partnered programs (e.g. GSK, Novartis, CYTLIMIC and EOC Pharma)

• ✓ Validation of LAG-3/MHC-II interaction by RELATIVITY-047 results

Notes:

30

N.B. The actual timing of future data readouts may differ from expected timing shown above. These dates are provided on a calendar year basis. A tick denotes that the item has been completed.

Summary

Global leadership position in LAG-3 with 4 LAG-3 related product candidates in immuno-oncology and autoimmune disease

Compelling clinical data from efti & strong rationale to combine with multiple FDA approved treatments

==> picture [170 x 60] intentionally omitted <==

Multiple active clinical trials (including partnered candidates), with further significant data read-outs in 2022

Established collaborations with e.g. Merck (MSD), Pfizer, Merck KGaA, Novartis and GSK

31

Thank you!